ETTX Stock - Entasis Therapeutics Holdings Inc.
Unlock GoAI Insights for ETTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $7.00M | $5.00M | N/A |
| Gross Profit | N/A | N/A | $7.00M | $5.00M | N/A |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | N/A |
| Operating Income | $-47,141,000 | $-54,231,000 | $-46,936,000 | $-38,207,000 | $-31,344,000 |
| Net Income | $-47,141,000 | $-50,496,000 | $-43,850,000 | $-32,952,000 | $-29,923,000 |
| Net Margin | N/A | N/A | -626.4% | -659.0% | N/A |
| EPS | $-1.00 | $-2.10 | $-3.33 | $-9.64 | $-8.05 |
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Visit WebsiteEarnings History & Surprises
ETTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2022 | Aug 10, 2022 | $-0.28 | — | — | — |
Q2 2022 | Apr 27, 2022 | $-0.26 | $-0.32 | -23.1% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.32 | $-0.29 | +9.4% | ✓ BEAT |
Q2 2021 | May 5, 2021 | $-0.36 | $-0.29 | +19.4% | ✓ BEAT |
Q1 2021 | Mar 23, 2021 | $-0.39 | $-0.13 | +66.7% | ✓ BEAT |
Q4 2020 | Nov 5, 2020 | $-0.50 | $-0.37 | +26.0% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | $-0.74 | $-0.78 | -5.4% | ✗ MISS |
Q2 2020 | May 7, 2020 | $-1.00 | $-1.15 | -15.0% | ✗ MISS |
Q1 2020 | Mar 11, 2020 | $-0.68 | $-1.06 | -55.9% | ✗ MISS |
Q4 2019 | Nov 14, 2019 | $-0.87 | $-0.27 | +69.0% | ✓ BEAT |
Q3 2019 | Aug 12, 2019 | $-0.60 | $-1.02 | -70.0% | ✗ MISS |
Q2 2019 | May 14, 2019 | $-0.75 | $-0.99 | -32.0% | ✗ MISS |
Q1 2019 | Mar 29, 2019 | $-0.80 | $-2.36 | -195.0% | ✗ MISS |
Q4 2018 | Nov 14, 2018 | $-0.90 | $-20.00 | -2122.2% | ✗ MISS |
Q3 2018 | Sep 26, 2018 | — | $-0.46 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-1.42 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-1.22 | — | — |
Q3 2017 | Sep 30, 2017 | — | $-1.11 | — | — |
Latest News
Frequently Asked Questions about ETTX
What is ETTX's current stock price?
What is the analyst price target for ETTX?
What sector is Entasis Therapeutics Holdings Inc. in?
What is ETTX's market cap?
Does ETTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ETTX for comparison